Details for Patent: 8,461,179
Which drugs does patent 8,461,179 protect, and when does it expire?
Patent 8,461,179 protects QINLOCK and is included in one NDA.
Summary for Patent: 8,461,179
| Title: | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| Abstract: | The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. |
| Inventor(s): | Daniel L. Flynn, Michael D. Kaufman, Peter A. Petillo |
| Assignee: | Deciphera Pharmaceuticals LLC |
| Application Number: | US13/491,394 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,461,179
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 8,461,179 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
